Racial variation in the uptake of oncotype DX testing for early-stage breast cancer

Journal of Clinical Oncology

Volumn 34, Issue 2, 2016, Pages 130-138

  Roberts, Megan C ^a   Weinberger, Morris ^a,b   Dusetzina, Stacie B ^a   Dinan, Michaela A ^a,c   Reeder Hayes, Katherine E ^a   Carey, Lisa A ^a   Troester, Melissa A ^a   Wheeler, Stephanie B ^a  

^a University of North Carolina at Chapel Hill   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CONTROLLED STUDY; DIAGNOSTIC TEST; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HUMAN; MAJOR CLINICAL STUDY; MINORITY GROUP; ONCOTYPE DX TESTING; POISSON DISTRIBUTION; PRIORITY JOURNAL; RACE DIFFERENCE; SOCIAL STATUS; TUMOR VOLUME; AFRICAN AMERICAN; AGED; BREAST TUMOR; CHEMISTRY; ECONOMICS; EPIDEMIOLOGY; ETHNOLOGY; GENE EXPRESSION PROFILING; INSURANCE; LYMPH NODE METASTASIS; METHODOLOGY; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NORTH CAROLINA; PATHOLOGY; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREDICTIVE VALUE; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ADULT; AFRICAN AMERICANS; AGED; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; GENE EXPRESSION PROFILING; HEALTHCARE DISPARITIES; HUMANS; INSURANCE COVERAGE; LYMPHATIC METASTASIS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NORTH CAROLINA; POISSON DISTRIBUTION; PRACTICE GUIDELINES AS TOPIC; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS;

EID: 84954116027     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.2489     Document Type: Article

References (41)

1. American Cancer Society: Breast cancer overview. http://www.cancer.org/cancer/breastcancer/overviewguide/breast-cancer-overviewkey-statistics
2. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:11-30, 2013
3. Toole MJ, Kidwell KM, Van Poznak C: Oncotype dx results in multiple primary breast cancers. Breast Cancer 8:1-6, 2014
4. Elder EE, Hay SB, Moore K: Factors influencing treatment recommendations in nodenegative breast cancer. J Oncol Pract 7:26-30, 2011
5. Reed SD, Dinan MA, Schulman KA, et al: Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decisionmaking to guide chemotherapy for earlystage breast cancer. Genet Med 15:203-211, 2013
6. Trosman JR, Van Bebber SL, Phillips KA: Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay. J Oncol Pract 6: 238-242, 2010
7. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
8. Asad J, Jacobson AF, Estabrook A, et al: Does Oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surg 196:527-529, 2008
9. Albanell J, Gonźalez A, Ruiz-Borrego M, et al: Prospective transGEICAM study of the impact of the 21-gene recurrence score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. Ann Oncol 23: 625-631, 2012
10. Biroschak JR, Schwartz GF, Palazzo JP, et al: Impact of Oncotype DX on treatment decisions in ERpositive, node-negative breast cancer with histologic correlation. Breast J 19:269-275, 2013
11. de Boer RH, Baker C, Speakman D, et al: The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer. Med J Aust 199:205-208, 2013
12. Henry LR, Stojadinovic A, Swain SM, et al: The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 99:319-323, 2009
13. Chavez-MacGregor M, Niu J, Smith B, et al: Oncotype Dx use and its relationship with chemotherapy administration in the general population. Presented at the American Associate for Cancer Research San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2014
14. Hornberger J, Cosler LE, Lyman GH: Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 11:313-324, 2005
15. Lyman GH, Cosler LE, Kuderer NM, et al: Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: An economic analysis based on prognostic and predictive validation studies. Cancer 109:1011-1018, 2007
16. Sparano JA: TAILORx: Trial assigning individualized options for treatment (Rx). Clin Breast Cancer 7:347-350, 2006
17. Albain KS, Barlow WE, Shak S, et al: Breast Cancer Intergroup of North America: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 11:55-65, 2010
18. Dowsett M, Cuzick J, Wale C, et al: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 28:1829-1834, 2010
19. Goldstein LJ, Gray R, Badve S, et al: Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26:4063-4071, 2008
20. Ramsey SD, Barlow WE, Gonzalez-Angulo AM, et al: Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. Contemp Clin Trials 34:1-9, 2013
21. Agency for Healthcare Research and Quality: National Healthcare Disparities Report, 2013. AHRQ publication no. 14-0006, Rockville, MD, 2014
22. Lund MJ, Mosunjac M, Davis KM, et al: 21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome. Cancer 118: 788-796, 2012
23. Guth AA, Fineberg S, Fei K, et al: Utilization of Oncotype DX in an inner city population: race or place? Int J Breast Cancer 2013:653805, 2013
24. DeFrank JT, Salz T, Reeder-Hayes K, et al: Who gets genomic testing for breast cancer recurrence risk? Public Health Genomics 16:215-222, 2013
25. Hassett MJ, Silver SM, Hughes ME, et al: Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol 30:2218-2226, 2012
26. Dinan MA, Mi X, Reed SD, et al: Initial trends in the use of the 21-gene recurrence score assay for patients with breast cancer in the Medicare population, 2005-2009. JAMA Oncol 1:158-166, 2015
27. Rothman KJ: Episheet: spreadsheets for the analysis of epidemiologic data. http://www.krothman. org/episheet.xls
28. Hebert PL, Sisk JE, Howell EA: When does a difference become a disparity? Conceptualizing racial and ethnic disparities in health. Health Aff (Millwood) 27:374-382, 2008
29. Nelson A: Unequal treatment: confronting racial and ethnic disparities in health care. J Natl Med Assoc 94:666-668, 2002
30. Zou G: A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 159:702-706, 2004
31. Zou GY, Donner A: Extension of the modified Poisson regression model to prospective studies with correlated binary data. Stat Methods Med Res 22:661-670, 2013
32. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502, 2006
33. Spellman E, Sulayman N, Eggly S, et al: Conveying genomic recurrence risk estimates to patients with early-stage breast cancer: oncologist perspectives. Psychooncology 22:2110-2116, 2013
34. Roberts MC, Bryson A, Weinberger M, et al: Barriers and facilitators for the use of oncotype DX among oncologists: A qualitative study.Presented at Academy Health Annual Research Meeting, Minneapolis, MN, June 14-16, 2015
35. Genomic Health, Inc: Getting tested with the Oncotype DX breast cancer assay. http://breastcancer.oncotypedx.com/en-US/Patient-Invasive/GettingTested.aspx
36. Murthy VH, Krumholz HM, Gross CP: Participation in cancer clinical trials: race-, sex-, and agebased disparities. JAMA 291:2720-2726, 2004
37. Albain KS, Unger JM, Crowley JJ, et al: Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 101:984-992, 2009
38. Bremnes RM, Andersen K, Wist EA: Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy. Eur J Cancer 31A:1955-1959, 1995
39. Hayman JA, Fairclough DL, Harris JR, et al: Patient preferences concerning the trade-off between the risks and benefits of routine radiation therapy after conservative surgery for early-stage breast cancer. J Clin Oncol 15:1252-1260, 1997
40. Roberts MC, Weinberger M, Dusetzina SB, et al: Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving Oncotype DX testing. Breast Cancer Res Treat 153: 191-200, 2015
41. Schenker N, Raghunathan TE, Chiu P, et al: Multiple imputation of missing income data in the National Health Interview Survey. J Am Stat Assoc 101:924-933, 2006